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Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the 
most common comorbidities associated with overweight 
and metabolic syndrome (MetS). Importantly, NAFLD 
is one of its most dangerous complications because it 
can lead to severe liver pathologies, including fibrosis, 
cirrhosis and hepatic cellular carcinoma. Given the 
increasing worldwide prevalence of obesity, NAFLD 
has become the most common cause of chronic liver 
disease and therefore is a major global health problem. 
Currently, NAFLD is predominantly regarded as a he-
patic manifestation of MetS. However, accumulating 
evidence indicates that the effects of NAFLD extend 
beyond the liver and are negatively associated with a 
range of chronic diseases, most notably cardiovascular 
disease (CVD), diabetes mellitus type 2 (T2DM) 
and chronic kidney disease (CKD). It is becoming 
increasingly clear that these diseases are the result 
of the same underlying pathophysiological processes 
associated with MetS, such as insulin resistance, 
chronic systemic inflammation and dyslipidemia. As 
a result, they have been shown to be independent 
reciprocal risk factors. In addition, recent data have 
shown that NAFLD actively contributes to aggravation 
of the pathophysiology of CVD, T2DM, and CKD, as 
well as several other pathologies. Thus, NAFLD is a 
direct cause of many chronic diseases associated with 
MetS, and better detection and treatment of fatty liver 
disease is therefore urgently needed. As non-invasive 
screening methods for liver disease become increasingly 
available, detection and treatment of NAFLD in patients 
with MetS should therefore be considered by both (sub-) 
specialists and primary care physicians. 
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Core tip: Given the increasing worldwide incidence of 
obesity and metabolic syndrome, non-alcoholic fatty 
liver disease (NAFLD) has become the most common 
cause of chronic liver disease. Recent developments 
in the field have shown that NAFLD not only is a 
“liver disease” but also is the underlying cause of an 
increasing number of extrahepatic manifestations; thus, 
it should be treated as a multisystem disease. NAFLD 
is most prominently linked to chronic kidney disease, 
mellitus type 2 and cardiovascular disease, as well 
as a number of other severe chronic diseases. These 
findings demonstrate that NAFLD ranks amongst the 
most serious public health problems of our time. 
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INTRODUCTION
The overall incidence of nonalcoholic fatty liver disease 
(NAFLD) is increasing along with that of obesity and 
metabolic syndrome (MetS). Therefore, NAFLD is the 
most frequent form of chronic liver disease that is 
closely related to MetS and its individual components 
[diabetes mellitus type 2 (T2DM), dyslipidemia, 
obesity and arterial hypertension]. NAFLD is diagnosed 
in people who do not have a history of excessive 
urination, do not have any other secondary causes 
of chronic liver disease (autoimmune and metabolic 
liver diseases, viral hepatitis) and do not use medi­
cation that can lead to liver steatosis. The clinical 
presentation of NAFLD varies from simple steatosis to 
nonalcoholic steatohepatitis (NASH), liver cirrhosis and 
hepatocellular carcinoma (HCC). NASH­related cirrhosis 
and NASH­related HCC are expected to become the 
most common indications for liver transplantation in 
the near future. Despite NAFLD’s substantial effects on 
liver physiology, the major causes of death in patients 
with NAFLD are, in fact, malignant and cardiovascular 
diseases (CVD), whereas liver­related mortality is 
only the third cause of mortality in these patients[1­3]. 
However, recent studies have shown that NAFLD 
affects several extra­hepatic organs and regulatory 
pathways and may be an important underlying cause 
of mortality related to failure of other organs than the 
liver. Recent findings have indicated that NAFLD is a 
new risk factor for extrahepatic diseases, such as CVD, 
chronic kidney disease (CKD), colorectal carcinoma, 
T2DM and psoriasis. All major studies of the NAFLD­
related chronic diseases during the past 10 years have 
involved CKD, CVD and T2DM. The clinical implication 
of this new evidence is that patients with NAFLD 
will benefit from more intensive surveillance and/or 
early treatment interventions to lower the incidence 
of diseases related to NAFLD[1­4]. In this review, we 
discuss the evidence linking NAFLD to extrahepatic 
diseases. 
CARDIOVASCULAR MANIFESTATIONS 
OF NAFLD
Coronary artery disease (CAD) and stroke compose 
more than 75% of CVD, which is the leading cause of 
death worldwide[4,5]. Primary and secondary preven­
tion of CVD are unsatisfactory throughout the world, 
and although the risk factors are well established, the 
incidence of CVD is still increasing. Abdominal obesity, 
arterial hypertension, T2DM and dyslipidemia are all 
features of MetS and have been repeatedly found in 
NAFLD. These findings prompt the question of whether 
NAFLD is a symptom of MetS or a consequence[6]. 
Numerous studies have examined this question, and 
the majority have suggested that NAFLD is the hepatic 
manifestation of the MetS[6]. Consequently, patients 
with these conditions are also at an increased risk for 
CVD because the common risk factors are shared[7­9]. 
Along with the epidemic of obesity, the prevalence of 
MetS and NAFLD is increasing globally and is emerging 
as a major public health problem. 
Several retrospective hospital­based studies with 
reasonably long follow­up have reported that patients 
with NAFLD have a higher all­cause and CVD­related 
mortality than that in the general population[4,10­16]. 
Retrospective studies assessing the relationship bet­
ween NAFLD and CVD risk are summarized in Table 1. 
Table 2 summarizes the prospective studies inves­
tigating the relationship between NAFLD and CVD 
risk, which have indicated that most NAFLD patients 
experience CVD events in the long term[17­25].
EVIDENCE RELATING NAFLD TO CVD
NAFLD is linked to increased CVD risk; hence, it is 
critical to evaluate the markers of subclinical CVD and 
NAFLD. Subclinical atherosclerosis can be detected 
by several markers, such as increased carotid 
intima­media thickness, increased coronary artery 
calcification, impaired flow-mediated vasodilation and 
increased arterial stiffness, all of which have been 
investigated and strongly correlated with NAFLD, 
independently of classical CVD risk factors and MetS 
features[26]. 
Other factors associated with CVD found in NAFLD 
are endothelial dysfunction, impaired left ventricular 
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(LV) function, epicardial fat, and clinical manifestations, 
such as obstructive sleep apnea syndrome and 
microangiopathic consequences[12]. 
CLINICAL AND SUBCLINICAL CVD AND 
NAFLD MARKERS 
CVD risk in patients with NAFLD is related to increased 
carotid intima media thickness (IMT), which is a 
characteristic of subclinical atherosclerosis and an 
important predictor of myocardial infarction, and the 
presence of carotid atherosclerotic plaques[12,27­30]. The 
strong relationship between increased IMT and NAFLD 
has been confirmed in several studies indicating that 
NAFLD predicts an increased carotid IMT independently 
of traditional cardiometabolic risk factors[12,31­36]. 
Salvi et al[37] have evaluated the relationship be­
tween NAFLD and subclinical vascular damage and have 
found that NAFLD was associated with MetS in 48% of 
the cases. In the same paper, IMT values were strongly 
related to the number of metabolic syndrome factors. 
In a study by Targher et al[38]; the severity of 
liver histology in NAFLD is strongly correlated with 
initial carotid atherosclerosis, independently of 
classical risk factors, thus indicating that the degree 
of liver damage may be important in atherosclerosis 
progression. Subclinical cardiovascular disease is 
shown to be closely associated with the severity of 
liver disease[38,39].
Arterial stiffness is an independent marker of 
symptomatic CVD and is measured by pulse wave 
velocity[40]. It indicates a loss of arterial elastic pro­
perties, which is linked to increased pulse pressure, 
LV hypertrophy, subendocardial ischemia, endothelial 
dysfunction and cardiac fibrosis[41]. Several studies 
have reported a strong association between NAFLD 
and impaired arterial elastic characteristics[36,37,40,42­44]. 
Furthermore, Lee et al[45] have found an independent 
association between arterial stiffness and the risk of 
NAFLD regardless of established CVD risk factors. 
Circulatory endothelial dysfunction is one of 
the earliest­appearing markers of atherosclerosis. 
Disfunction is defined as brachial artery flow-mediated 
dilatation, and is significantly lower in patients with 
NAFLD compared with non­steatotic controls, thus 
indicating that NAFLD is associated with endothelial 
dysfunction, separately from MetS[44]. Villanova et al[46] 
have reported that NAFLD without MetS is strongly 
associated with increased carotid IMT. 
The relationship between the degree of fatty 
liver severity and epicardial fat thickness has been 
described in obese NAFLD patients[12,47]. Epicardial fat 
correlates with MetS, abdominal visceral adiposity, 
atherosclerosis and CAD[12,48­50]. As a source of 
vasoactive products and cytokines, it may regulate 
coronary arterial tone and influence CAD, atrial 
fibrillation, systolic dysfunction and heart failure[12,51­55]. 
Cardiac steatosis has been found to be a strong 
predictor of LV diastolic dysfunction in a study where 
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Table 1  Principal retrospective studies of cardiovascular diseases mortality and morbidity risk in patients with nonalcoholic fatty 
liver disease (published in the past 10 years)
Ref. Study design Study size Diagnosis of 
NAFLD
Follow-up 
duration (yr)
Adjusted 
clinical 
variables
Major findings
Ekstedt et al[13] Retrospective; 
Hospital-based
  129 Histological 13.7 Matched for 
gender, age 
and country
NASH subjects (not those with simple steatosis) 
had higher rates of all-cause, CVD and liver-related 
mortality than the general population
Stepanova et 
al[15]
Retrospective; 
Population-based
  289 Histological 6.25 No 
adjustments 
made
Higher risk of liver-related mortality in NASH than 
non-NASH. NAFLD and type II diabetes had the 
highest risk for overall and liver-related mortality
Ekstedt et al[14] Retrospective; 
Community-based
  229 Histological 26.4 NAFLD patients had increased risk of death, with 
a high risk of death from CVD and liver-related 
disease
Fibrosis stage predicted all-cause, CVD and liver-
related death
Rafiq et al[10] Retrospective; 
Hospital-based
  173 Histological 13 No 
adjustments 
made
Higher liver-related mortality but no difference in 
overall mortality (NASH vs simple steatosis)
Soderberg et 
al[11]
Retrospective; 
Hospital-based
  118 Histological 18 Matched for 
gender, age 
and year
Increased total mortality in NAFLD was 
predominantly CV-related compared with matched 
reference population
Dunn et al[16] Retrospective cohort 2343 Computed 
tomography
  5 No significant association was found between 
NAFLD and risk of all-cause mortality and cause-
specific
(CVD, cancer and liver) mortality and morbidity. 
NAFLD patients 
(steatosis > 30% on imaging) averaged 8 yr younger 
than those without NAFLD
NAFLD: Nonalcoholic fatty liver disease; CVD: Cardiovascular diseases; NASH: Nonalcoholic steatohepatitis.
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dysfunction. Goland et al[62] were the first to report 
that NAFLD patients, in the absence of obesity, 
hypertension, and T2DM, have altered LV geometry 
and features of LV diastolic dysfunction. Fallo et al[63] 
have reported that NAFLD is significantly associated 
with insulin resistance and LV diastolic function, thus 
suggesting a parallel increase in metabolic and cardiac 
risk. 
On the basis of the above findings, NAFLD may 
subjects with a higher intra­hepatic fat content had a 
significantly higher myocardial fat content[2,56].
Coronary artery calcification (CAC) ascertained 
by computed tomography is considered to be an 
independent marker of CVD risk[57]. A study conducted 
in 2007 in subjects with MetS identified an independent 
association of NAFLD with CAC[58]. Similar results have 
been reported by several other researchers[59­61]. 
NAFLD is also correlated with impaired LV diastolic 
Table 2  Principal prospective studies of cardiovascular diseases mortality and morbidity risk in patients with nonalcoholic fatty liver 
disease (published in the past 10 years)
Ref. Study design Study 
size
Diagnosis of 
NAFLD
Follow-up 
duration (yr)
Adjusted clinical variables Major findings
Targher et al[17] Prospective; 
Hospital-
based
2013 Ultrasound 6.5 Gender, age, BMI, smoking status, diabetes 
duration, alcohol consumption, BP, HbA1c, TG, 
HDL, LDL cholesterol, GGT, use of medications 
(anti-hyperglycemic, antihypertensive, lipid-
lowering, or anti-platelet drugs), and metabolic 
syndrome
NAFLD was independently 
associated with increased risk 
of nonfatal CVD events and 
CVD mortality
Hamaguch et 
al[18]
Prospective; 
Community-
based
1637 Ultrasound 5.0 Gender, age, BMI, smoking, alcohol consumption, 
BP, TG, HDL, LDL cholesterol, MetS
NAFLD was independently 
associated with increased risk 
of nonfatal CVD events
Haring et al[19] Prospective; 
Community-
based
4160 Ultrasound 7.3 Gender, age, WC, diabetes, alcohol consumption, 
BP, physical activity, education level, civil status, 
equalized income, and Functional Co-morbidity 
Index
NAFLD was independently 
associated with increased risk 
of all-cause and CVD mortality 
in men
Wong et al[24] Prospective; 
Hospital-
based
612 Ultrasound 1.8 Gender, age, BMI, WC, smoking status, diabetes, 
alcohol consumption, BP, fasting glucose, ALT, 
TG, HDL, LDL cholesterol, creatinine
NAFLD was independently 
associated with an increased 
prevalence of CVD at baseline, 
but there was no significant 
association between NAFLD 
and risk of incident CVD 
events
Lazo et al[28] Prospective; 
Population-
based
11371 Ultrasound 14.3 Gender, age, ethnicity, BMI, education, smoking 
status, BP, alcohol consumption, physical 
activity, hypercholesterolemia diabetes
Independent increased risk 
of CVD but no significant 
association between NAFLD 
and all-cause and cause-
specific (CVD, cancer and liver) 
mortality
Stepanova et 
al[22]
Zhou et al[20] Prospective; 
Community-
based
3324 Ultrasound   4.0 No adjustment made Patients with NAFLD had 
about 3-fold higher rates of all-
cause and CVD mortality than 
those without NAFLD
Treeprasertsuk 
et al[25]
Prospective; 
Community-
based
309 Ultrasound/
CT
11.5 Gender, age Framingham risk score 
accurately predicted the 
higher 10-yr CAD risk in 
NAFLD patients and was the 
only variable significantly 
associated with the risk of 
developing new onset CVD 
events
Kim et al[23] Prospective; 
Population-
based
11154 Ultrasound 
and 
advanced 
fibrosis score 
systems
14.5 Gender, age, ethnicity, education, income, 
diabetes, BP, history of CVD, lipid-lowering 
medication, smoking status, WC, alcohol 
consumption, caffeine consumption, total and 
HDL cholesterol, transferrin saturation, and CRP
NAFLD was not associated 
with increased all-cause 
mortality. However, NAFLD 
with advanced hepatic fibrosis 
was independently associated 
with increased risk of all-cause 
mortality. Increase in mortality 
was almost entirely from CVD 
causes
NAFLD: Nonalcoholic fatty liver disease; BMI: Body mass index; BP: Blood pressure; TG: Triglycerides; GGT: Gamma-glutamyl transferase; MetS: 
Metabolic syndrome; WC: Waist circumference; ALT: Alanine aminotransferase; CRP: C-reactive protein; CVD: Cardiovascular diseases; NASH: 
Nonalcoholic steatohepatitis.
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be an independent contributor to the development 
of atherosclerosis and other structural and functional 
cardiac alterations, which subsequently lead to clinical 
CVD and potentially an increased risk of congestive 
heart failure (HF). 
Similar results have been shown in two large 
population­based cohort studies (more than 7000 
subjects) in which serum liver enzyme­diagnosed 
NAFLD has been found to be independently associated 
with an increased incidence of HF[64­66]. 
Atrial fibrillation (AF) is one of the consequences of 
diastolic dysfunction. Few studies have examined the 
relationship between NAFLD and risk of incident AF 
in subjects with T2DM. NAFLD has been shown to be 
associated with an increased risk of AF, independently 
of gender, age, hypertension, LV hypertrophy and PR 
interval[12,67,68]. Additionally, a prospective study of 
nearly 1000 subjects has reported that NAFLD is an 
independent risk factor of AF[69].
NAFLD is also associated with prolonged QTc 
interval (strong predictor of ventricular arrhythmias 
and sudden cardiac death[70,71]) in T2DM even after 
adjusting for multiple known risk factors, which is a 
viable interpretation of the increased CVD mortality 
associated with NAFLD[2,72]. 
Echocardiographic findings of aortic valve scle­
rosis have been linked with NAFLD, independently 
of established CVD risk factors, in both diabetic 
and non­diabetic individuals[2,73,74]. Moreover, the 
ultrasonographic severity of NAFLD and LV diastolic 
dysfunction are significantly associated. 
PATHOPHYSIOLOGICAL MECHANISMS 
LINKING NAFLD AND CVD
Although several well­established common risk 
factors explain the association between CVD and 
NAFLD, the precise pathophysiological mechanisms 
underlying this complex relationship are still unclear. 
Numerous pathophysiological mechanisms link these 
two diseases, including oxidative stress, atherogenic 
dyslipidemia, subclinical inflammation, insulin 
resistance, endothelial dysfunction and an abnormal 
adipokine profile, as shown in Figure 1[12].
Many studies have shown that components of 
oxidative stress (possibly initiated by NAFLD) may 
be involved in the pathogenesis of CVD and increase 
CVD risk[75­78]. In patients with NAFLD, high levels 
of triglycerides and low levels of HDL­C have been 
observed, which indicates atherogenic dyslipide­
mia[12,79]. Atherogenic dyslipidemia in conjunction with 
insulin resistance and abdominal visceral adiposity 
constitutes the major factor involved in accelerated 
atherosclerosis[12,80­82].
Hepatic accumulation of lipids causes subacute 
liver inflammation[12]. Atherosclerosis has been 
correlated with liver damage, with increased levels in 
patients with simple steatosis and especially in NASH 
patients[12]. Additionally, patients with NAFLD have 
increased levels of circulating endothelial progenitor 
cells (EPC), such levels are associated with the 
severity of NAFLD. According to recent manuscript, 
these cells may play a role in the early natural history 
Figure 1  Pathophysiological mechanisms linking obesity, nonalcoholic fatty liver disease, cardiovascular disease, chronic kidney disease and diabetes 
mellitus type 2. NAFLD: Nonalcoholic fatty liver disease; RAAS: Renin-angiotensin-aldosterone system.
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of NAFLD. EPC might be increased in an attempt to 
repair the endothelial damage resulting from metabolic 
alterations accompanying NAFLD[83]. 
Insulin resistance is a crucial contributor to NAFLD, 
MetS and atherosclerosis. Increased liver fat content 
appears to be the best independent predictor of IR 
in skeletal muscle, adipose tissue, and the liver[84,85]. 
Hence, with more advanced stages of NAFLD, liver 
fat is progressively increased, thus increasing the 
risk of CVD. NAFLD may act as a stimulus for further 
increased whole­body IR and dyslipidemia (with a 
typical overproduction of triglyceride and cholesterol­
rich remnant particles), thereby leading to increased 
atherosclerosis[84,86].
Reduced adiponectin secretion, which has anti­
atherogenic, anti­inflammatory and anti­fibrotic 
characteristics, in conjunction with increased leptin 
secretion, which has the opposite effects, promotes 
progression of fatty steatosis to NASH and CVD[12]. 
Additionally, TNF­a and IL­6 released from the 
abdominal visceral fat influence mitochondrial and 
endothelial dysfunction and increase free fatty acids 
levels, which contribute to atherosclerosis and CAD 
progression[12,87­89]. 
NAFLD AND CVD GENETICS
The underlying genetic bases of both NAFLD and CAD 
have been widely studied, and recenly reviewed by Li 
et al[90]. The authors have reviewed the literature on 
gene polymorphisms of the leptin receptor (LEPR), 
apolipoprotein C3 (APOC3), adiponectin­encoding gene 
(ADIPOQ), peroxisome proliferator­activated receptors 
(PPAR), sterol regulatory element­binding proteins 
(SREBP), microsomal triglyceride transfer protein 
(MTTP), transmembrane 6 superfamily member 2 
(TM6SF2), tumor necrosis factors­alpha (TNF­α) and 
manganese superoxide dismutase (MnSOD), all of 
which have been linked to NAFLD and CAD. 
Most consistently reported gene is patatin­like 
phospholipase­3 (PNPLA3, known as adiponutrin)[12]. 
Petta et al[91] have evaluated carotid atherosclerosis in 
NAFLD patients and have reported that the PNPLA3 GG 
genotype is associated with a higher severity of carotid 
atherosclerosis in younger subjects with NAFLD. 
PNPLA3 gene variants may increase lipid storage in 
the arterial walls and also induce release of ICAM­1, 
an endothelium­derived inflammatory marker that 
has been associated with myocardial infarction and 
stroke[12,92]. 
Key considerations
NAFLD is an independent contributor to CVD pro­
gression and is associated with an enhanced risk of 
cardiovascular disease, regardless of the established 
risk factors. The risk of CVD mortality may be greater 
in subgroups with a necro-inflammatory form of NAFLD 
(e.g., NASH) and advanced fibrosis, compared with 
subgroups with simple steatosis. Given the incidence 
of these diseases, it is of clinical and scientific interest 
to further elucidate the underlying mechanisms of 
liver progression to prevent CVD complications. 
NAFLD patients should be screened for CVD diseases, 
as has been proposed by many authors. Further 
studies should demonstrate how modification of the 
underlying liver disease progression may affect CVD 
outcome, to determine whether NAFLD treatment, and 
consequently the reversion of liver disease, can lower 
the incidence of CVD. 
DIABETES MELLITUS AND NAFLD
Epidemiology of diabetes and NAFLD
T2DM is a multi­factorial disease, in which the body 
no longer properly responds to physiological insulin 
concentrations, generally as a result of chronic 
hypernutrition and obesity. Hepatic IR, in addition to 
chronic dyslipidemia, appears to be a key underlying 
mechanism of NAFLD[93]. Therefore, NAFLD and DM 
often occur within the same patient. Epidemiological 
studies have shown that 18%­33% of individuals with 
NAFLD also have T2DM and as many as 66%­83% 
of those with fatty liver disease have some form of 
insulin resistance[94­96]. In a study in which NAFLD 
patients were subjected to two­step hyperinsulinemic 
euglycemic clamp analysis all subjects with NAFLD 
were shown to be insulin resistant[97].
T2DM is a key risk factor for the development of 
severe liver diseases[95]. NAFLD patients with T2DM, 
compared with people without this disease, have 
a 2.6­fold higher risk of developing NASH[98]. This 
risk further increases with increasing body weight. 
The prevalence of NASH development in obese 
T2DM patients with NAFLD may be as high as 40%, 
whereas it is less than 5% in people without T2DM[99]. 
T2DM is linked to an accelerated rate of liver fibrosis 
progression[100] and strongly increases the risk of 
developing cirrhosis[101]. Miele and colleagues have 
shown that T2DM patients, compared with controls, 
have an almost threefold higher risk of developing 
hepatocellular carcinoma[102]. As a result, T2DM 
increases the risk of liver­related death in NAFLD 
patients by up to 22­fold[103]. 
Finally, a large prospective study has shown 
that NAFLD increased the chances of developing 
nonfatal coronary heart disease, ischemic stroke, or 
cardiovascular death by more than 50% in T2DM 
patients[104]. It is still unknown how NAFLD promotes 
cardiovascular disease in T2DM, and pharmacological 
therapy that increases the risk of developing CVD 
should therefore be avoided in this patient group[105,106]. 
Pathophysiology of diabetes and NAFLD
Although IR appears to be essential for the develop­
ment of both fatty liver disease and T2DM, an inability 
of the liver to sense insulin is by itself does not induce 
Mikolasevic I et al . NAFLD - Multisystem disease
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NAFLD. This is illustrated by the observation that 
liver disease is common but not universal in T1DM 
patients[107]. Consistently with the “multiple hit” theory, 
additional risk factors, such as obesity, poor glycemic 
control and age, are associated with development of 
NAFLD in individuals with T1DM[108]. 
A key event in the development of NAFLD appears 
to be the deregulation of insulin­mediated control of 
hepatic production of glucose and lipids. In healthy 
individuals, insulin impairs gluconeogenesis while 
promoting lipogenesis. In NAFLD, especially in the 
context of T2DM, a paradoxical situation occurs in 
that IR results in a reduced ability to inhibit gluconeo­
genesis, whereas insulin­driven lipogenesis still occurs 
and is even enhanced. These circumstances have led 
to the hypothesis that hepatic IR is partial, limiting 
the Akt signaling arm while still allowing for SREBP1c 
activation[109]. Indeed, animal studies have shown 
that hepatic elimination of the insulin receptor does 
not result in higher levels of triglycerides (TG) in the 
liver or in circulation[110]. Defects in Akt signaling result 
in increased gluconeogenesis, whereas impaired 
activation of PKCλ is associated with hypolipidemia and 
decreased expression of SREBP1c[111]. 
To assess the model of selective hepatic post­
receptor insulin resistance in humans, Semple RK 
and colleagues have studied a number of patients 
with rare mutations in either the insulin receptor or 
in the protein kinase Akt2[112]. Patients with primary 
defects at the level of the insulin receptor did not have 
metabolic dyslipidemia. In contrast, patients with Akt2 
mutations showed marked metabolic dyslipidemia with 
elevated fasting TG, high VLDL/TG/cholesterol ratios, 
low HDL cholesterol levels and high small dense LDL 
levels. Additionally, liver fat and hepatic lipogenesis 
were strongly increased in these patients. 
A second factor that contributes to the aggravation 
of NAFLD in T2DM is obesity­induced chronic systemic 
inflammation, which originates in visceral adipose 
tissue[113]. When adipocytes become hypertrophic 
as a result of hypernutrition, their access to proper 
oxygenation is reduced[114], and they become physically 
restricted by the stromal matrix[115]. Hypertrophic 
adipocytes therefore induce expression of stress ligands 
on their cell membrane, thus activating the local immune 
system and driving a sterile inflammatory response 
in adipose tissue[116]. As obesity progresses, adipose 
tissue inflammation is aggravated, ultimately leading 
to the release of pro­inflammatory cytokines[116­118]. 
The increased amount of free fatty acids (FFAs) in 
circulation, caused by IR, stimulates FFA uptake by 
the liver, thus contributing to lipid accumulation and 
inflammation in the liver and development of NAFLD[119]. 
In summary, the clinical complications of T2DM and 
NAFLD are both dependent on IR. However, differences 
in secondary aggravating factors indicate that treatment 
of one disease will not necessarily result in improvement 
in the symptoms of the other (Figure 1). 
Key considerations
NAFLD is associated with a two to five times higher 
risk for development of T2DM. Many authors have 
suggested screening for T2DM in patients with NAFLD 
by periodically performing simple laboratory tests. 
Additionally, NAFLD patients with T2DM have a 2.6­fold 
higher risk of developing NASH compared with patients 
without this disease[98]. This risk further increases with 
body weight. The prevalence of NASH development 
in obese T2DM patients with NAFLD may be as high 
as 40%, whereas it is less than 5% in people without 
T2DM[99]. T2DM is associated with an accelerated rate 
of liver fibrosis progression[100] and strongly increases 
the risk of developing cirrhosis[101]. In addition, T2DM 
is associated with a higher prevalence of hepatic 
malignancies in NAFLD patients. As a result, T2DM 
increases the risk of liver­related death in NAFLD 
patients by up to 22­fold. Future studies should deter­
mine which screening regimens for liver disease should 
be applied to which T2DM patients. Additionally, it is 
not clear to what extent NAFLD contributes to T2DM 
and whether improvement of its clinical parameters 
might lower the risk for development of T2DM. 
Moreover, it is not known whether treatment of NAFLD 
could improve glycemic control in NAFLD patients who 
have developed T2DM.
NONALCOHOLIC FATTY LIVER DISEASE 
AND CHRONIC KIDNEY DISEASE
The prevalence of chronic kidney disease (CKD) is 
approximately 4.3%­13% in the general population, 
but it is expected to increase[4]. Because there is a 
high death risk primarily associated with adverse 
cardiovascular events, less than half of CKD patients 
develop end­stage renal disease (ESRD). Patients 
with CKD stage three may benefit the most from 
early referral strategies. There are many well­known 
risk factors that contribute to the progression of 
CKD, such as obesity, arterial hypertension, and 
T2DM. Recognizing groups of patients at risk for 
CKD is a clinical challenge. Owing to high morbidity, 
mortality and healthcare costs related to CKD, many 
scientists have sought to elucidate the underlying 
cause of CKD, and identification of modifiable risk 
factors for CKD has attracted increasing attention. 
Recent data have shown that IR and MetS are related 
to an increased incidence of albuminuria and CKD. 
The strongest evidence for this pathogenic link is 
that arterial hypertension and T2DM are the major 
etiological factors of CKD. As shown by many authors, 
NAFLD and CKD are related to the same group of 
cardiometabolic risk factors, including MetS and its 
individual components, and they are both associated 
with an increased risk of incident CVD events. 
CKD and NAFLD have several common traditional 
and non­traditional cardiometabolic risk factors, 
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including higher hemostatic and plasma factors, 
lower circulating insulin­like growth factor­1 (IGF­1) 
levels, hyperuricemia, oxidative stress biomarkers 
and endothelial dysfunction. Recent studies have 
shown a correlation between CKD and NAFLD: there 
is a significantly higher prevalence of CKD in patients 
with NAFLD/NASH compared with patients without 
NAFLD/NASH[1,3,4,120­124]. Thus, it is not surprising 
that the connection between NAFLD, IR and MetS 
suggests that NAFLD may predict the occurrence of 
CKD. Moreover, data from the United Network Organ 
Sharing database from 2002­2011 have revealed an 
increase in NASH­related cirrhosis after simultaneous 
liver­kidney transplantation[1,123,125]. It is difficult to 
determine a causal relationship between CKD and 
NAFLD, owing to similarity in traditional risk factors for 
NAFLD and CKD. 
EPIDEMIOLOGICAL EVIDENCE LINKING 
NAFLD AND CKD
On the basis of earlier observations that approximately 
90% of patients with NAFLD have more than one 
component of MS, and 35%­75% of patients meet the 
diagnostic criteria, it is not surprising that patients with 
NAFLD may also have decreased renal function[126]. To 
date, many cross­sectional and retrospective studies 
involving patients with and without diabetes have 
shown that the prevalence of CKD in patients with 
NAFLD is increasing. In the majority of studies, the 
relationship between CKD and NAFLD is independent 
of co­morbidities, such as MetS and IR[127­131]. CKD is 
defined by decreased estimated glomerular filtration 
rate (eGFR) and/or the presence of significant pro­
teinuria. By detecting elevated liver enzymes, such 
as gamma­glutamyl transferase (GGT) or alanine 
aminotransferase (ALT), or by imaging techniques, 
primarily abdominal ultrasound, researchers diagnosed 
NAFLD. Notably, approximately half of the patients’ 
aminotransferase levels, which are used as a marker 
of liver damage, were normal. Accordingly, in patients 
with normal aminotransferase values, NAFLD and 
liver fibrosis cannot be excluded; thus, the results of 
these studies should be carefully interpreted[121,126­131]. 
Although it is an invasive technique with possible 
sampling mistakes, liver biopsy remains the “gold 
standard” in diagnosing and staging NAFLD[126]. In 
the literature, few studies have used liver biopsy for 
detection and grading of NAFLD in the context of CKD. 
Interestingly, patients from a study with histologically 
defined NASH had lower eGFR and higher prevalence of 
CKD or abnormal albuminuria than matched controls. 
A study by Targher et al[132] has shown that individuals 
with biopsy-confirmed NASH had moderately decreased 
eGFR and more frequent abnormal albuminuria and 
CKD than the matched control group. Additionally, the 
severity of NASH histology was related to decreased 
kidney function, independently of traditional risk 
factors, MetS components and IR. Yilmaz et al[133] have 
come to similar conclusions. 
Our group has examined the association between 
NAFLD and decreased kidney function. We have used 
transient elastography (TE) with controlled attenuation 
parameter (CAP) for NAFLD detection. In patients with 
CKD stages 3 and 4, we have found a high prevalence 
of NAFLD. In this study, the severity of liver steatosis 
defined by CAP had a negative correlation with kidney 
function[134,135]. Because one third of the population 
has NAFLD, it is not possible to perform liver biopsy in 
such large groups. Therefore, TE with CAP may be a 
reasonable screening method for NAFLD, but further 
studies are needed. 
Another interesting study by Sesti et al[124] has 
evaluated whether the severity of liver fibrosis estimated 
by NAFLD fibrosis score is related to the higher 
prevalence of CKD in patients with NAFLD. eGFR and 
NAFLD fibrosis scores were assessed in 570 patients 
with ultrasonography­diagnosed NAFLD. Subjects with a 
high probability of liver fibrosis had a 5.1-fold increased 
risk of having CKD (OR = 5.13, 95%CI: 1.13­23.28, P 
= 0.03) compared with individuals at a low probability 
after adjustment for gender, age and BMI. After 
adjustment for statin therapy, glucose tolerance status 
and anti­hypertensive treatment in addition to gender, 
patients with a high probability of liver fibrosis had a 
3.9­fold increased risk of CKD (OR = 3.94, 95%CI: 
1.11­14.05, P = 0.03) compared with individuals at a 
low probability. 
A remaining question regarding the connection 
between CKD and NAFLD is whether NAFLD is 
only a risk marker or a pathogenic factor of CKD 
development. Several prospective studies have 
evaluated the relationship between NAFLD and the 
development of CKD. These studies have shown that 
NAFLD is independently associated with an increased 
risk of CKD and/or microalbuminuria; the HR was 1.49 
to 4.38[136­139]. Similar conclusions have been reached 
retrospective study by Jia et al[140]. Unfortunately, no 
studies have assessed whether changes in NAFLD 
(either development of the severe form of NAFLD or 
resolution of NAFLD) modify the risk of incidence of 
CKD during the follow­up period[3].
In 2014, a meta­analysis of 33 studies was per­
formed with a total of over two thousand participants 
and has confirmed the relationship between NAFLD 
and CKD[141]. In this meta­analysis, NAFLD has 
been found to be correlated with an increasing risk 
of prevalent (OR = 2.12, 95%CI: 1.69­2.66) and 
incident (HR = 1.79, 95%CI: 1.65­1.95) CKD. Notably, 
NASH was associated with a higher prevalence (OR = 
2.53, 95%CI: 1.58­4.05) and incidence (HR = 2.12, 
95%CI: 1.42­3.17) of CKD than simple steatosis. 
Furthermore, advanced fibrosis was correlated with a 
higher prevalence (OR = 5.20, 95%CI: 3.14­8.61) and 
incidence (HR = 3.29, 95%CI: 2.30­4.71) of CKD than 
non-advanced fibrosis[141,142].
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MECHANISM LINKING NAFLD TO CKD
Because NAFLD and CKD share many significant 
cardiometabolic risk factors, it should come as no 
surprise that these two diseases are closely associated. 
It is crucial to understand the mechanism linking 
these two conditions because new strategies for 
CKD prevention or treatment and its associated co­
morbidities may arise from novel insights into the 
underlying mechanism. The key questions regarding 
the link between these two conditions are (1) whether 
shared cardiometabolic risk factors are the basis of 
the association; (2) or whether NAFLD itself may, 
independently of shared cardiometabolic risk factors, 
contribute to CKD development; and (3) or whether 
the CKD development risk is dependent on the 
degree of liver disease in patients with NAFLD. These 
questions will determine whether the risk is increased 
with the severity of liver disease, such as NASH and/or 
liver fibrosis presence or development[74].
Lipid and glucose metabolism is predominantly 
regulated by the liver, which is also a major source of 
inflammatory mediators linked with the pathogenesis 
of CKD and CVD. IR is the key pathophysiological 
factor for the development and progression of NAFLD. 
In addition, IR has been attributed to the development 
of CKD. Obesity is a known independent risk factor for 
CKD. Similarly, MetS and obesity have been described 
as strong predictors for the development of NAFLD[121]. 
The secretion of numerous classical biomarkers of 
inflammation and endothelial dysfunction is partly 
dependent on factors that are unregulated in the 
presence of IR and the MetS, and are principally 
produced by the liver. Therefore, a link between 
the liver and the inflamed adipose tissue, which 
releases FFA and secretes several proinflammatory 
adipokines, is likely. IR is a major pathogenic factor 
in the development of NAFLD and its associated 
comorbidities because it increases FFA uptake in the 
liver. As mentioned above, IR is a possible mechanism 
that links NAFLD and CKD, because it is a risk factor 
for CKD[3]. When there is an increased influx of FFA, 
and chronic inflammation is present, the target 
and contributing factor in systemic inflammation is 
probably the liver. Therefore, the increased expression 
of intrahepatic cytokines mediated by hepatocellular 
damage and fat­derived factors may have a role in the 
progression of CKD in NAFLD[74,121,126,143].
Other pathophysiological mechanisms may be 
contributing factors in CKD development in patients 
with NAFLD. NAFLD patients, for example, have 
decreased plasma adiponectin levels, which are 
inversely correlated with the degree of NAFLD. An 
inverse correlation has also been found between 
adiponectin levels and proteinuria[3,74,144]. Ix et al[144] 
have explained this association several years ago. 
According to the authors, the mechanism that leads to 
NAFLD and CKD, occurring due to fat, liver and kidney 
communication, is established through two serum 
proteins: fetuin­A and adiponectin, whose serum levels 
are associated with key components of MetS, but in 
opposite directions. High serum levels of fetuin­A have 
been found in patients with NAFLD and CKD. Fetuin­A 
inhibits adiponectin synthesis and is also an inductor of 
inflammatory signaling and IR, which are major factors 
driving T2DM, CVD and CKD development[3,74,144].
Another “puzzle” believed to be a link between 
NAFLD and CKD is the renin­angiotensin system 
(RAS). The expression levels of all RAS components 
in hepatic stellate cells (HSC) in healthy liver are very 
low. As such, HSCs are normally unable to secrete 
angiotensin II (Ang II). When activated by hepatic 
injury, HSCs and other hepatic myofibroblasts express 
numerous components of the RAS, including receptor 
of angiotensin­converting enzyme and the angiotensin 
1 (AT1) receptor. As a result, contraction and pro­
liferation of HSCs via the AT1 receptor are induced 
because HSCs can synthesize Ang II. In the liver, IR 
and de novo lipogenesis are promoted by Ang II, as 
well as the production of proinflammatory cytokines. 
A range of fibrogenic actions (which includes cell 
migration, cell proliferation and collagen synthesis) is 
also stimulated by Ang II. The hypothesis that HSCs 
are activated and differentiated into myofibroblasts 
through Ang II promotion has been supported by recent 
studies. In addition, Ang II promotes inflammatory 
cytokine release, as well as extracellular matrix protein 
deposition in excessive amounts (Figure 1)[121,145].
Key considerations 
A popular area of scientific research is the emerging 
evidence linking NAFLD and CKD. Many authors agree 
that NAFLD (in particular, biopsy­proven NASH) is 
associated with a greater prevalence of CKD, in spite 
of the limitations of the studies that investigated the 
association between NAFLD and CKD. Furthermore, 
NAFLD is associated with an increased risk of 
prevalence and incidence of CKD. Simple steatosis 
is associated with a lower prevalence and incidence 
of CKD than the necroinflammatory form of NAFLD 
(e.g., NASH). Additionally, non­advanced fibrosis is 
associated with a lower prevalence and incidence 
of CKD than advanced fibrosis. These data suggest 
that CKD is associated with the stage of liver disease. 
According to the available literature, it is still not clear 
whether NAFLD is only an indicator of increased risk of 
CKD or is actively involved in the pathogenesis of CKD. 
However, most authors support the hypothesis that 
NAFLD is one of the pathophysiological mechanisms 
in the development and progression of CKD. Certainly, 
further prospective research is necessary to determine 
whether NAFLD is only an indicator of CKD or is actively 
involved in the pathogenesis of CKD[3,4,74,121,122,146]. 
The mechanisms linking NAFLD and CKD have 
not been completely elucidated, but these conditions 
share common cardiometabolic risk factors and 
the final clinical consequence of increased CVD 
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morbidity and mortality. The prevalence of NAFLD is 
continuously increasing in concert with the epidemic 
of its risk factors: obesity and MetS and its individual 
components. The increase in simultaneous liver­kidney 
transplantation as well as the significant cost linked 
with CKD in the NAFLD population indicate that this 
relationship is a worthwhile target for screening and 
therapeutic intervention[3,4,74,121,122,146].
We expect that in the future, there will be an 
increase in CKD incidence, given the association 
of NAFLD and CKD. Treatment modalities that will 
lower the comorbidity burden linked with NAFLD 
may consequently decrease the risk of CKD. Future 
research should determine whether the treatment 
of liver disease will ultimately prevent or delay the 
development and progression of CKD. Moreover, future 
studies regarding NAFLD treatment should include the 
renal function as one end­point.
The major risk factor that defines the prognosis of 
all chronic liver disease, including NAFLD, is fibrosis. 
To identify patients who require stringent clinical 
surveillance to prevent development or progression of 
both liver and renal complications, researchers can use 
noninvasive methods to predict fibrosis in subjects with 
NAFLD. Further studies to identify noninvasive markers 
for practical detection of NAFLD in large populations 
are needed. TE with CAP may be useful. On the basis 
of current knowledge about the association between 
CKD and NAFLD, patients with NAFLD should benefit 
from regular (annual) screening for CKD, which may 
include an analysis of simple laboratory parameters, 
such as the determination of serum creatinine and 
albuminuria. Then, physicians who manage those 
patients should not only focus on liver disease but 
also recognize extra­hepatic manifestations of NAFLD. 
Additionally, physicians who manage patients with 
impaired renal function should also screen patients for 
NAFLD[3,4,74,121,122,124,126,146].
NONALCOHOLIC FATTY LIVER DISEASE 
AND COLORECTAL CANCER
Colorectal cancer (CRC) is one of the most common 
tumors worldwide. Inflammatory bowel disease and 
genetic factors are well­known risk factors for the 
development of CRC. Recent studies have shown that 
75%­95% of all colorectal carcinomas are not caused 
by genetic factors but are related to lifestyle factors. 
Preventive colonoscopy examinations, detection of 
precursors (polyps) and polypectomy are necessary to 
reduce the development of invasive cancer[147­151].
The search for new risk factors for developing 
colon polyps as well as colon cancer is of interest to 
many researchers. Numerous studies support the 
hypothesis that patients with MetS have an increased 
risk of CRC and that IR is associated with an increased 
risk of developing CRC. MetS occurs as a result of 
the modern lifestyle. This hypothesis is supported by 
studies showing that some of the factors of IR (insulin 
and insulin­like growth factor 1 and 2) promote the 
progression of precursor CRC (colon polyps) to invasive 
adenocarcinoma. Therefore, some authors believe 
that patients with diabetes should undergo frequent 
endoscopic examinations of the colon[148­151].
Studies conducted in recent years have demons­
trated the importance of MS, IR and chronic inflam­
mation in the pathogenesis of CRC. Additionally, 
decreased levels of adiponectin promote malignant 
alteration of cells in the colon. On the other hand, the 
primary result of NAFLD is increased production of 
different proinflammatory factors and procoagulant 
factors from an “inflamed liver”. As stated previously, 
patients with NAFLD have reduced levels of protective 
adipokines and adiponectin. Therefore, common 
factors among NAFLD, colon polyps and CRC in­
clude IR, chronic inflammation, oxidative stress and 
decreased levels of adiponectin[2,4,147,148,149,150,152]. In 
recent years, an increasing number of publications 
have identified NAFLD as an independent risk factor 
for the development of adenomatous polyps and 
CRC[147­153]. For example, Lee et al[152] have analyzed 
5517 patients, 833 of whom had NAFLD detected 
by abdominal ultrasound. The authors have found 
that patients with NAFLD had twice the risk of 
adenomatous polyps and a three times greater risk 
of developing CRC. The importance of the increased 
risk for developing CRC in patients with NAFLD is 
discussed in a study by Wong et al[153], who have used 
histopathological analysis to detect NAFLD and have 
found that the presence of NAFLD was associated 
with an increased incidence of adenomatous polyps 
and precancerous lesions of the colon. Notably, the 
researchers have found that patients with simple 
steatosis were not at increased risk. The authors have 
concluded that the presence of NAFLD is associated 
with a high incidence of colorectal adenomas and high­
grade colorectal carcinomas. The largest number of 
adenomas was localized in the right colon. The authors 
of this study strongly support screening for CRC in 
these high­risk patients.
Key considerations
Research conducted to date has suggested a possible 
association between NAFLD and the risk of adenoma 
polyp development and CRC, although they are very 
heterogeneous. Future studies are necessary to confirm 
the risk of CRC and adenomas in patients with NAFLD. 
Further research should determine whether screening 
for CRC is necessary in these patients and whether it 
is necessary for young patients with MetS and NAFLD. 
Additionally, future studies should determine whether 
patients with NAFLD require more frequent and earlier 
preventive colonoscopy examinations to reduce 
morbidity and mortality from CRC.
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NONALCOHOLIC FATTY LIVER DISEASE 
AND PSORIASIS
Psoriasis is a chronic inflammatory immune­mediated 
skin disease, which is associated with various comor­
bidities. Its prevalence in is 2%­3% worldwide[154­157]. 
Currently, psoriasis has been proposed to be not 
only disease of the skin but also a complex condition 
with multisystem involvement. Moreover, psoriasis is 
linked with MetS: cardiometabolic risk factors (e.g., 
hypertension, obesity, T2DM and dyslipidemia) are 
more common in patients with psoriasis than in the 
general population, thus conferring an increased 
CVD risk. It is believed that the underlying low and 
persistent inflammatory status with increased levels of 
pro-inflammatory cytokines (TNF-α, IL­6) is responsible 
for the metabolic dysregulation and for the higher CVD 
risk in this skin disease. Furthermore, preliminary data 
have shown that psoriasis is related to pro­thrombotic 
conditions. To date, multiple studies have confirmed 
the association between NAFLD and chronic plaque 
psoriasis[154­158]. Recent studies have shown that the 
prevalence of NAFLD, diagnosed either by imaging or 
by histology, is higher in patients with psoriasis (with 
prevalence up to 50% of these patients) compared 
with controls. Psoriasis is associated with NAFLD even 
after taking into account MetS components and other 
potential confounding factors. Several researchers 
believe that psoriatic patients are more likely to 
develop advanced forms of NAFLD than non­psoriatic 
controls and that NAFLD patients have more severe 
psoriasis than those without it[158­162]. A recent meta­
analysis by Candia et al[163] of seven case­control 
studies has found that psoriatic patients have a twofold 
higher rate of NAFLD compared with people without 
psoriasis. Among patients with more severe psoriasis 
or psoriatic arthritis, this risk is even higher. However, 
it is important to note that the cross­sectional design 
of the abovementioned studies cannot ascertain the 
temporality and causality of the relationship between 
NAFLD and psoriasis[158]. 
Given that NAFLD and psoriasis, have a strong 
connection with MetS, these findings are not surprising. 
A chronic inflammatory state is the major characte­
ristic of NAFLD patients. Thus, a low, subchronic 
inflammatory state may serve as the connection 
between NAFLD and psoriasis. Psoriasis and obesity 
are directly related; psoriasis predicts the development 
of obesity and MetS. Therefore, NAFLD and psoriasis 
may be linked by obesity itself, which may contribute 
to the development of further MetS components and 
comorbidities. Consistently with this hypothesis is the 
earlier observation that excess adipose tissue results in 
unbalanced pro- and anti-inflammatory mediators and 
that stronger inflammatory stimulation is responsible 
for the initiation of the subchronic inflammatory 
state. The pathogenesis of both psoriasis and NAFLD 
depends on several cytokines, both proinflammatory 
(TNF­α, IL­6, leptin, visfatin) and anti­inflammatory 
(adiponectin) cytokines. Additionally, adiponectin 
levels are lower in patients affected by both NAFLD 
and psoriasis than in patients affected by psoriasis 
without NAFLD[154,155­158,164­168]. Another hypothesis 
is that NAFLD itself can contribute to the severity of 
psoriasis by releasing proinflammatory cytokines from 
the liver[154].
Key consideration
The available literature indicates that the prevalence 
of NAFLD is higher in patients with psoriasis (up to 
50% of these patients), regardless of coexisting MetS 
symptoms. Additionally, patients with psoriasis have 
a higher risk for developing the more severe forms 
of NAFLD. Therefore, patients with chronic plaque 
psoriasis should be carefully monitored and evaluated 
for NAFLD. The cross­sectional design of this study 
cannot determine the temporality and causality of 
the association between NAFLD and psoriasis. More 
studies are needed in the future to determine whether 
NAFLD is only an epiphenomenon of the coexisting 
MetS features or is an independent risk factor for the 
development and progression of psoriasis. Until then, 
patients with psoriasis would benefit from frequent 
NAFLD and MetS screening to decrease the incidence 
of CVD events and liver­related complications. 
Further studies are also necessary to elucidate the 
pathophysiological mechanisms connecting NAFLD 
with psoriasis. It must be considered that some 
medications can be hepatotoxic and have negative 
effects on metabolic comorbidities (including NAFLD). 
The data on the relationship between use of TNF­α 
inhibitor and NAFLD are contradictory. Consequently, 
more studies should be performed to examine the 
influence of biological agents on histological features 
of NAFLD in psoriatic patients. Until then, patients 
with psoriasis may benefit from lifestyle interventions, 
such as diet and exercise, as well as from treatment of 
associated MetS components[154]. 
NONALCOHOLIC FATTY LIVER DISEASE, 
POLYCYCSTIC OVARIAN SYNDROME 
AND OBSTRUCTIVE SLEEP APNEA 
SYNDROME 
Polycystic ovary syndrome (PCOS) affects appro­
ximately 5%­11% women, and it is one of the most 
common endocrine disorders. The most important 
feature of PCOS is clinical and/or laboratorial 
hyperandrogenism. Hyperinsulinemia is very common 
amongst women with PCOS. Insulin and luteinizing 
hormone act synergistically, stimulating ovarian 
theca cells to increase androgen synthesis, inhibiting 
synthesis of the steroid hormone binding globulin 
by the liver and increasing the amount of free and 
biologically active testosterone in circulation. Because 
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IR is the characteristic of MetS, several reports have 
shown that women with PCOS are more likely to have 
MetS c[169­171]. Other studies have shown that women 
with PCOS, regardless of their body weight, have a 
higher risk for the development of NAFLD. The results 
by Gutierrez­Grobe Y[172] suggest that NAFLD is more 
prevalent in postmenopausal and women with PCOS 
than those premenopausal ones. They have concluded 
that estrogens may have a protective effect of against 
NAFLD in women. Published studies of the coherence 
between PCOS and NAFLD are still very rare. Further 
studies are needed to confirm the relationships be­
tween these conditions[4,169].
In the past few years, several experiments have 
suggested the possibility of a connection between 
chronic intermittent hypoxia of obstructive sleep 
apnea syndrome (OSAS) and NAFLD[4]. Musso et al[173] 
have included eighteen cross­sectional studies (2183 
participants) in their meta­analysis. They have found 
a correlation between OSAS and increased risk for 
NAFLD, NAS and fibrosis. In this meta­analysis, the 
pooled odds ratios (ORs) of OSAS for the presence 
of NAFLD, as defined by histology, radiology, and 
AST or ALT elevation, were 2.01 2.99, 2.36 and 2.60, 
respectively. The pooled ORs of OSAS for NASH, 
fibrosis­any stage, or advanced fibrosis in biopsy­
proven NAFLD patients were 2.37, 2.16 and 2.30, 
respectively. The authors have emphasized the need 
for screening OSAS patients for the presence and 
severity of NAFLD[172]. However, further studies are 
needed.
CONCLUSION 
During the past decade, it has been confirmed 
that NAFLD is more than just a “liver disease”. The 
vast amount of evidence linking NAFLD with other 
extrahepatic diseases indicates that it is a multisystem 
disease. On the basis of the literature, the strongest 
evidence exists between NAFLD and CKD, CVD and 
T2DM. The biggest question regarding the association 
between NAFLD, CVD, CKD and T2DM is whether 
NAFLD is only a risk factor or a pathogenic factor for 
these conditions. Currently, most of the studies and 
their authors support the hypothesis that NAFLD is 
one of the pathophysiological mechanisms in the 
development and progression of CVD, CKD and T2DM, 
but further prospective studies are needed[2,4]. 
NAFLD is a public health problem that increases in 
magnitude on a daily basis. Owing to its numerous poten­
tial extrahepatic manifestations, most (sub­)specialists, 
and even primary care physicians, should be aware 
of this condition, especially now that many diagnostic 
methods are available for screening in clinical practice[2,4].
Another interesting question is whether it is possible 
to prevent the appearance or progression of CKD, CVD 
and T2DM by treating liver conditions (e.g., NAFLD). 
Theoretically, treatment modalities that minimize the 
comorbidities associated with NAFLD may consequently 
decrease the risk of developing CKD, CVD and T2DM. 
Therefore, future studies should determine whether 
treatment of the liver would preclude or postpone 
the development and advancement of CKD, CVD and 
T2DM[2,4].
Preliminary research has convincingly revealed a 
connection between NAFLD with CRC and psoriasis. 
Further studies may determine whether screening 
for CRC is required in these patients and whether 
screening for CRC at young patients with MS (NAFLD) 
is necessary. These studies should answer the 
question of whether patients suffering from NAFLD 
require earlier preventive colonoscopy to decrease the 
mortality and morbidity due to CRC[2,4].
Despite the cumulative evidence that NAFLD 
(specifically NASH and fibrosis) is an important risk 
factor for extrahepatic disease, current guidelines 
have yet to include any recommendations for 
screening for these complications. As discussed 
above, adequately powered and prospective studies 
using comparable inclusion criteria (e.g., NAFLD 
diagnosis) will be required to confirm the incidence 
risk of specific extrahepatic disease among different 
NAFLD populations. In addition, future studies will 
be necessary to evaluate the cost effectiveness and 
risk: benefit balance of screening. However, until 
the results of these studies and new guidelines 
for obligatory screening are obtained, we strongly 
believe that NAFLD patients would benefit from 
CVD, CKD and T2DM screening by using simple and 
easily accessible clinical and laboratory methods. For 
screening for T2DM, we recommend frequently­used 
laboratory analyses, such as measuring fasting and 
postprandial serum glucose values and determination 
of Hb1Ac levels. Serum creatinine analyses as well 
as urine analysis are adequate and simple methods 
of screening for CKD. Finally, periodic measurements 
(at least once a year) of arterial blood pressure, lipid 
profile determination, body weight measurement 
and determination of central obesity would be good 
screening methods for CVD. Additionally, information 
on smoking history and physical activity could be 
included. Given the morbidity and mortality caused by 
CRC, patients with NAFLD would probably benefit from 
assessment of various risk factors, such as positive 
family history, smoking, alcohol consumption, and the 
presence of T2DM and obesity, as well as frequent 
colon symptom analysis[2,4]. 
In summary, NAFLD is a disease that extends 
beyond the liver, negatively affecting chronic diseases 
and substantially affecting people’s health. Future 
treatment of patients with NAFLD should therefore 
account for the both the benefits and risks of comor-
bidities associated with this important disease. 
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